Simplified quantification of cerebral A1 adenosine receptors using [18F]CPFPX and PET: Analyses based on venous blood sampling

Synapse

Volumn 55, Issue 4, 2005, Pages 212-223

  Meyer, Philipp T ^a   Elmenhorst, David ^a   Zilles, Kael ^a   Bauer, Andreas ^a  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

18F CPFPX; A1 adenosine receptor; Kinetic modelling; Non invasive; PET

Indexed keywords

8 CYCLOPENTYL 3 (3 FLUOROPROPYL) 1 PROPYLXANTHINE F 18; ADENOSINE A1 RECEPTOR; FLUORINE 18; TRACER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTERIAL BLOOD; ARTICLE; BLOOD SAMPLING; BOLUS INJECTION; BRAIN TISSUE; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; IN VIVO STUDY; ISOTOPE LABELING; MALE; NON INVASIVE MEASUREMENT; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; RELIABILITY;

ADULT; ALGORITHMS; AREA UNDER CURVE; ARTERIES; ARTIFACTS; BLOOD CHEMICAL ANALYSIS; BODY FLUID COMPARTMENTS; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RECEPTOR, ADENOSINE A1; REPRODUCIBILITY OF RESULTS; VEINS; XANTHINES;

EID: 13844252050     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20113     Document Type: Article

References (29)

1. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. 1999. Hum Brain Mapp 7:254-266.
2. Bauer A, Holschbach MH, Cremer M, Weber S, Boy C, Shah NJ, Olsson RA, Halling H, Coenen HH, Zilles K. 2003a. Evaluation of 18F-CPFPX, a novel adenosine A1 receptor ligand: in vitro autoradiography and high-resolution small animal PET. J Nucl Med 44:1682-1689.
3. Bauer A, Holschbach MH, Meyer PT, Boy C, Herzog H, Olsson RA, Coenen HH, Zilles K. 2003b. In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography. Neuroimage 19:1760-1769.
4. Burger C, Buck A. 1997. Requirements and implementation of a flexible kinetic modeling tool. J Nucleic Med 38:1818-1823.
5. Carrillo JA, Christensen M, Ramos SI, Aim C, Dahl ML, Benitez J, Bertilsson L. 2000. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 22:409-417.
6. Carson RE, Channing MA, Blasberg RG, Dunn BB, Cohen RM, Rice KC, Herscovitch P. 1993. Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab 13:24-42.
7. Cunha RA. 2001. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem Int 38:107-125.
8. Dunwiddie TV, Masino SA. 2001. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 24:31-55.
9. Glass M, Faull RL, Bullock JY, Jansen K, Mee EW, Walker EB, Synek BJ, Dragunow M. 1996. Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Res 710:56-68.
10. Haas HL, Selbach O. 2000. Functions of neuronal adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 362:375-381.
11. Holschbach MH, Fein T, Krummeich C, Lewis RG, Wutz W, Schwabe U, Unterlugauer D, Olsson RA. 1998. A1 adenosine receptor antagonists as ligands for positron emission tomography (PET) and single-photon emission tomography (SPET). J Med Chem 41:555-563.
12. Holschbach MH, Olsson RA, Bier D, Wutz W, Sihver W, Schuller M, Palm B, Coenen HH. 2002. Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. J Med Chem 45:5150-5156.
13. Ito H, Koyama M, Goto R, Kawashima R, Ono S, Atsumi H, Ishii K, Fukuda H. 1995. Cerebral blood flow measurement with iodine-123-IMP SPECT, calibrated standard input function and venous blood sampling. J Nucleic Med 36:2339-2342.
14. Laruelle M, al-Tikriti MS, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, Innis RB. 1994. In vivo quantification of dopamine D2 receptor parameters in nonhuman primates with [123I]iodobenzofuran and single photon emission computerized tomography. Eur J Pharmacol 263:39-51.
15. Lassen NA. 1992. Neuroreceptor quantitation in vivo by the steady-state principle using constant infusion or bolus injection of radioactive tracers. J Cereb Blood Flow Metab 12:709-716.
16. Lassen NA, Perl W. 1979. Tracer kinetic models in medical physiology. New York: Raven Press.
17. Logan J, Fowler JS, Volkow ND, Ding YS, Wang GJ, Alexoff DL. 2001. A strategy for removing the bias in the graphical analysis method. J Cereb Blood Flow Metab 21:307-320.
18. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, Christman DR. 1990. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740-747.
19. Meyer PT, Bier D, Holschbach MH, Boy C, Olsson RA, Coenen HH, Zilles K, Bauer A. 2004. Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET. J Cereb Blood Flow Metab 24:323-333.
20. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. 1984. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217-227.
21. Nariai T, Shimada Y, Ishiwata K, Nagaoka T, Shimada J, Kuroiwa T, Ono K, Ohno K, Hirakawa K, Senda M. 2003. PET imaging of adenosine A(1) receptors with (11)C-MPDX as an indicator of severe cerebral ischemic insult. J Nucleic Med 44:1839-1844.
22. Perl W. 1971. Stimulus-response method for flows and volumes in slightly perturbed constant parameter systems. Bull Math Biophys 33:225-233.
23. Pinborg LH, Videbaek C, Hasselbalch SG, Sorensen SA, Wagner A, Paulson OB, Knudsen GM. 2001. Benzodiazepine receptor quantification in Huntington's disease with [(123)I] omazenil and SPECT. J Neurol Neurosurg Psychiatry 70:657-661.
24. Pinborg LH, Videbaek C, Svarer C, Yndgaard S, Paulson OB, Knudsen GM. 2002. Quantification of [(123)I]PE2I binding to dopamine transporters with SPET. Eur J Nucl Med Mol Imaging 29:623-631.
25. Ramkumar V, Hallam DM, Nie Z. 2001. Adenosine, oxidative stress and cytoprotection. Jpn J Pharmacol 86:265-274.
26. Ribeiro JA, Sebastiao AM, de Mendonca A. 2002. Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 68:377-392.
27. Slifstein M, Laruelle M. 2000. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. J Nucl Med 41:2083-2088.
28. Ulas J, Brunner LC, Nguyen L, Cotman CW. 1993. Reduced density of adenosine A1 receptors and preserved coupling of adenosine A1 receptors to G proteins in Alzheimer hippocampus: a quantitative autoradiographic study. Neuroscience 52:843-854.
29. Watabe H, Channing MA, Der MG, Adams HR, Jagoda E, Herscovitch P, Eckelman WC, Carson RE. 2000. Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907. J Cereb Blood Flow Metab 20:899-909.